
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc. has demonstrated an encouraging upward trend in revenue, achieving $422,000 in Q2, marking a significant increase from $197,000 in Q1. The company's projections indicate robust revenue growth, forecasting an increase to $1.3 million in 2025 and further to $4.5 million in 2026. This anticipated growth is underpinned by RenovoRx's innovative Trans-Arterial Micro-Perfusion therapy platform, aimed at addressing high unmet medical needs in cancer treatment, which positions the company well within the biopharmaceutical sector.
Bears say
RenovoRx Inc is facing significant challenges due to the high unmet medical need in the pancreatic cancer treatment market, where the 5-year survival rate is only 12%, highlighting the severe limitations in therapeutic options. The company reported a modest revenue of $0.4 million paired with a net loss of $2.9 million, indicating ongoing financial struggles that align closely with consensus estimates, thus offering little positive deviation to suggest financial improvement. Furthermore, while the company has potential in its proprietary therapy platform, the overwhelming concerns regarding its current performance and the market's harsh realities contribute to a negative outlook on its stock.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares